Current biomarkers for diagnosing of prostate cancer

Future Oncology

Volumn 11, Issue 20, 2015, Pages 2743-2755

  Stephan, Carsten ^a,b   Jung, Klaus ^a,b   Ralla, Bernhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

AUC; cancer; ETS; free PSA; kallikreins; PCA3; phi; prostate; prostate biopsy; prostate volume; PSA; PSA limitations; PSA subforms; ROC analysis; sarcosine; sensitivity; specificity; TMPRSS2; tumor marker; urine

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BETA MICROSEMINOPROTEIN; CALGRANULIN A; CALGRANULIN B; CAVEOLIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; KALLIKREIN; KALLIKREIN 1; KALLIKREIN 15; KALLIKREIN 2; KALLIKREIN 3; KALLIKREIN 5; LONG UNTRANSLATED RNA; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MICRORNA; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; SOMATOMEDIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR TMPRSS2; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CANCER RISK; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; GLEASON SCORE; GROUPS BY AGE; HUMAN; MALE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BLOOD; PROSTATIC NEOPLASMS; URINE;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84944720175     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.203     Document Type: Article

References (118)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87-108 (2015).
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest. Urol. 17(2), 159-163 (1979).
4. Lilja H, Ulmert D, Vickers AJ. Prostatespecific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8(4), 268-278 (2008).
5. Kuller LH, Thomas A, Grandits G, Neaton JD. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13(3), 373-377 (2004).
6. Vickers AJ, Ulmert D, Sjoberg DD et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 346, f2023 (2013).
7. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at
8. years of follow-up. Lancet 384(9959), 2027-2035 (2014).
9. Heijnsdijk EA, de Carvalho TM, Auvinen A et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J. Natl. Cancer Inst. 107(1), 366 (2015).
10. Buzzoni C, Auvinen A, Roobol MJ et al. Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer. Eur. Urol. doi:10.1016/j.eururo.2015.02.042 (2015) (Epub ahead of print).
11. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J. Urol. 162(2), 293-306 (1999).
12. Jiandani D, Randhawa A, Brown RE et al. The effect of bicycling on PSA levels: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. doi:10.1038/pcan. 2015.16 (2015) (Epub ahead of print).
13. Lilja H, Christensson A, Dahlen U et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37(9), 1618-1625 (1991).
14. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51(1), 222-226 (1991).
15. Stenman UH, Leinonen J, Zhang WM, Finne P. Prostate-specific antigen. Semin. Cancer Biol. 9(2), 83-93 (1999).
16. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin. Chem. 45, 814-821 (1999).
17. Zhang WM, Finne P, Leinonen J et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin. Chem. 44(12), 2471-2479 (1998).
18. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur. J. Cancer 43(13), 1918-1926 (2007).
19. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19), 1542-1547 (1998).
20. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9(11), 1133-1147 (2000).
21. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67(4), 762-768 (2006).
22. Stephan C, Cammann H, Meyer HA, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett. 249(1), 18-29 (2007).
23. Stephan C, Cammann H, Meyer HA et al. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int. 102(7), 799-805 (2008).
24. Finne P, Finne R, Auvinen A et al. Predicting the outcome of prostate biopsy in screenpositive men by a multilayer perceptron network. Urology 56(3), 418-422 (2000).
25. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostatespecific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 52(3), 455-461 (1998).
26. Virtanen A, Gomari M, Kranse R, Stenman U-H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin. Chem. 45, 987-994 (1999).
27. Babaian RJ, Ayala A, Johnston DA, Zhang Z. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml. Urology 56(6), 1000-1006 (2000).
28. Horninger W, Bartsch G, Snow PB, Brandt JM, Partin AW. The problem of cutoff levels in a screened population: appropriateness of informing screenees about their risk of having prostate carcinoma. Cancer 91(8 Suppl.), 1667-1672 (2001).
29. Stephan C, Cammann H, Semjonow A et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin. Chem. 48(8), 1279-1287 (2002).
30. Remzi M, Anagnostou T, Ravery V et al. An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 62(3), 456-460 (2003).
31. Finne P, Finne R, Bangma C et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int. J. Cancer 111(2), 310-315 (2004).
32. Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim. Biophys. Acta 1846(1), 99-112 (2014).
33. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 59(6), 797-802 (2002).
34. Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin. Chem. 49(2), 253-259 (2003).
35. Stephan C, Cammann H, Deger S et al. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology 74(4), 873-877 (2009).
36. Nurmikko P, Vaisanen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Production and characterization of novel anti-prostatespecific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin. Chem. 46(10), 1610-1618 (2000).
37. Mikolajczyk SD, Catalona WJ, Evans CL et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin. Chem. 50(6), 1017-1025 (2004).
38. Catalona WJ, Partin AW, Sanda MG et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J. Urol. 185(5), 1650-1655 (2011).
39. Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [-2]proprostatespecific antigen and the prostate health index for detecting prostate cancer. Clin. Chem. 59(1), 306-314 (2013).
40. Jansen FH, van Schaik RH, Kurstjens J et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur. Urol. 57(6), 921-927 (2010).
41. Lazzeri M, Haese A, de la Taille A et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur. Urol. 63(6), 986-994 (2013).
42. Sokoll LJ, Sanda MG, Feng Z et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 19(5), 1193-1200 (2010).
43. Abrate A, Lazzeri M, Lughezzani G et al. Clinical performance of the Prostate Health Index (PHI) for the prediction of prostate cancer in obese men: data from the PROMEtheuS project, a multicentre European prospective study. BJU Int. 115(4), 537-545 (2015).
44. de la Calle C, Patil D, Wei JT et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naive men. J. Urol. 194(1), 65-72 (2015).
45. Loeb S, Sanda MG, Broyles DL et al. The prostate health index selectively identifies clinically significant prostate cancer. J. Urol. 193(4), 1163-1169 (2015).
46. Lughezzani G, Lazzeri M, Haese A et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur. Urol. 66(5), 906-912 (2014).
47. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 112(6), 717-728 (2013).
48. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin. Chem. Lab. Med. 51(4), 729-739 (2013).
49. Abrate A, Lughezzani G, Gadda GM et al. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature. Korean J. Urol. 55(7), 436-445 (2014).
50. Ferro M, Bruzzese D, Perdona S et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin. Chim. Acta 413(15-16), 1274-1278 (2012).
51. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat. Rev. Urol. 10(1), 38-48 (2013).
52. Loeb S. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI) Yet more evidence that the PHI consistently outperforms PSA across diverse populations. BJU Int. 115(4), 500 (2015).
53. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22(2), 184-204 (2001).
54. Lundwall A, Band V, Blaber M et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387(6), 637-641 (2006).
55. Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M. Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer. Eur. Urol. 68(1), 139-146 (2015).
56. Shaw JL, Grass L, Sotiropoulou G, Diamandis EP. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin. Biochem. 40, 104-110 (2007).
57. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb. Haemost. 110(3), 484-492 (2013).
58. Stephan C, Rittenhouse H, Cammann H et al. New markers and multivariate models for prostate cancer detection. Anticancer Res. 29(7), 2589-2600 (2009).
59. Lucarelli G, Rutigliano M, Bettocchi C et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. J. Urol. 190(6), 2271-2277 (2013).
60. Balan V, Wang Y, Nangia-Makker P et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget 4(4), 542-549 (2013).
61. Koutros S, Meyer TE, Fox SD et al. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis 34(10), 2281-2285 (2013).
62. de Vogel S, Ulvik A, Meyer K et al. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer-a large nested case-control study within the JANUS cohort in Norway. Int. J. Cancer 134(1), 197-206 (2014).
63. Colleselli D, Stenzl A, Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur. Urol. 58(5), e51 (2010).
64. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem. 47(3), 282 (2010).
65. Danila DC, Anand A, Schultz N et al. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur. Urol. 65(6), 1191-1197 (2014).
66. Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 111(1), 17-21 (2013).
67. Ellinger J, Muller SC, Stadler TC, Jung A, von RA, Bastian PJ. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol. Oncol. 29(2), 124-129 (2011).
68. Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit. Rev. Clin. Lab. Sci. 51(4), 200-231 (2014).
69. Ellinger J, Muller SC, Dietrich D. Epigenetic biomarkers in the blood of patients with urological malignancies. Expert. Rev. Mol. Diagn. 15(4), 505-516 (2015).
70. Dietrich D, Meller S, Uhl B et al. Nucleic acid-based tissue biomarkers of urologic malignancies. Crit. Rev. Clin. Lab. Sci. 51(4), 173-199 (2014).
71. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009).
72. Jentzmik F, Stephan C, Miller K et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol. 58(1), 12-18 (2010).
73. Cernei N, Heger Z, Gumulec J et al. Sarcosine as a potential prostate cancer biomarker-a review. Int. J. Mol. Sci. 14(7), 13893-13908 (2013).
74. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52(6), 1089-1095 (2006).
75. Filella X, Foj L, Mila M, Auge JM, Molina R, Jimenez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol. 34(3), 1337-1347 (2013).
76. Haese A, de la Taille A, Van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol. 54(5), 1081-1088 (2008).
77. Deras IL, Aubin SM, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179(4), 1587-1592 (2008).
78. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69(3), 532-535 (2007).
79. Ankerst DP, Groskopf J, Day JR et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J. Urol. 180(4), 1303-1308 (2008).
80. Chun FK, de la Taille A, Van Poppel H et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol. 56, 659-668 (2009).
81. Hessels D, van Gils MP, van HO et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 70(1), 10-16 (2010).
82. Auprich M, Haese A, Walz J et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur. Urol. 58(5), 727-732 (2010).
83. Roobol MJ, Schroder FH, van LP et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur. Urol. 58(4), 475-481 (2010).
84. Ploussard G, Haese A, Van PH et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies BJU Int. 106(8), 1143-1147 (2010).
85. Aubin SM, Reid J, Sarno MJ et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J. Urol. 184(5), 1947-1952 (2010).
86. de la Taille A, Irani J, Graefen M et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J. Urol. 185(6), 2119-2125 (2011).
87. Perdona S, Cavadas V, Di LG et al. Prostate cancer detection in the "grey area" of prostatespecific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur. Urol. 59(1), 81-87 (2011).
88. Bollito E, De LS, Cicilano M et al. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy. Anal. Quant. Cytol. Histol. 34(2), 96-104 (2012).
89. Crawford ED, Rove KO, Trabulsi EJ et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J. Urol. 188(5), 1726-1731 (2012).
90. Stephan C, Jung K, Semjonow A et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin. Chem. 59(1), 280-288 (2013).
91. Hansen J, Auprich M, Ahyai SA et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur. Urol. 63(2), 201-209 (2013).
92. Ochiai A, Okihara K, Kamoi K et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 111(6), 928-933 (2013).
93. Scattoni V, Lazzeri M, Lughezzani G et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J. Urol. 190(2), 496-501 (2013).
94. Tombal B, Andriole GL, de la Taille A et al. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology 81(5), 998-1004 (2013).
95. Gittelman MC, Hertzman B, Bailen J et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J. Urol. 190(1), 64-69 (2013).
96. Ferro M, Bruzzese D, Perdona S et al. Prostate health index (PHI) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS ONE 8(7), e67687 (2013).
97. Goode RR, Marshall SJ, Duff M, Chevli E, Chevli KK. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 73(1), 48-53 (2013).
98. Ruffion A, Devonec M, Champetier D et al. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int. J. Mol. Sci. 14(9), 17767-17780 (2013).
99. Leyten GH, Hessels D, Jannink SA et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65(3), 534-542 (2014).
100. Tomlins SA, Day JR, Lonigro RJ et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol. doi:10.1016/j.eururo.2015.04.039 (2015) (Epub ahead of print).
101. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005).
102. Esgueva R, Perner S, LaFargue J et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod. Pathol. 23(4), 539-546 (2010).
103. Groskopf J, Siddiqui J, Aubin SMJ et al. Feasibility and clinical utility of a TMPRSS2:ERG gene fusion urine test [abstract]. Eur. Urol. Suppl. 8(4), 195 (2009).
104. Salami SS, Schmidt F, Laxman B et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. 31(5), 566-571 (2013).
105. Tomlins SA, Aubin SM, Siddiqui J et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl Med. 3(94), 94ra72 (2011).
106. Robert G, Jannink S, Smit F et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate 73(2), 113-120 (2013).
107. Stephan C, Cammann H, Jung K. The value of TMPRSS2:ERG. Eur. Urol. doi:10.1016/j. eururo.2015.04.008 (2015) (Epub ahead of print).
108. Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. Clin. Chem. Lab. Med. 53(7), 1109-1118 (2015).
109. Fleischhacker M, Schmidt B. Extracellular nucleic acids and cancer. In: Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring. Gahan PB (Ed.). Springer, Dordrecht, The Netherlands, 239-293 (2015).
110. Rigau M, Ortega I, Mir MC et al. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate 71(16), 1736-1745 (2011).
111. Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD. A multiplex model of combining gene-based, protein-based, and metabolitebased with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71(7), 700-710 (2011).
112. Katafigiotis I, Tyritzis SI, Stravodimos KG et al. Zinc alpha2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int. 110(11 Pt B), E688-E693 (2012).
113. Chwatko G, Forma E, Wilkosz J et al. Thiosulfate in urine as a facilitator in the diagnosis of prostate cancer for patients with prostate-specific antigen less or equal
114. ng/ml. Clin. Chem. Lab. Med. 51(9), 1825-1831 (2013).
115. Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J. Urol. 189(2), 422-429 (2013).
116. Roobol MJ, Haese A, Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol. 50(S1), 85-89 (2011).
117. Hessels D, Schalken JA. Urinary biomarkers for prostate cancer: a review. Asian J. Androl. 15(3), 333-339 (2013).
118. Seisen T, Roupret M, Brault D et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate 75(1), 103-111 (2015).